

Title (en)
ANTI-TUMOR EFFECT POTENTIATOR

Title (de)
POTENTIATOR FÜR ANTI-TUMOR-WIRKUNGEN

Title (fr)
POTENTIALISATEUR D'EFFET ANTICANCÉREUX

Publication
EP 2508185 A4 20160525 (EN)

Application
EP 10833385 A 20101129

Priority
• JP 2009272738 A 20091130
• JP 2010071280 W 20101129

Abstract (en)
[origin: US2012225838A1] There is provided an agent for potentiating the effects of an anti-tumor agent. An anti-tumor effect potentiator containing, as an active ingredient, a uracil compound represented by the following formula (I) or a pharmaceutically acceptable salt thereof: wherein X represents a C1-5 alkylene group and one of methylene groups constituting the alkylene group is optionally substituted with an oxygen atom; R1 represents a hydrogen atom or a C1-6 alkyl group; R2 represents a hydrogen atom or a halogen atom; and R3 represents a C1-6 alkyl group, a C2-6 alkenyl group, a C3-6 cycloalkyl group, a (C3-6 cycloalkyl) C1-6 alkyl group, a halogeno-C1-6 alkyl group or a saturated heterocyclic group.

IPC 8 full level
A61K 31/513 (2006.01); **A61K 31/519** (2006.01); **A61K 31/7072** (2006.01); **A61K 45/06** (2006.01); **A61P 35/00** (2006.01); **A61P 35/02** (2006.01); **A61P 43/00** (2006.01); **C07D 239/54** (2006.01); **C07D 405/12** (2006.01)

CPC (source: EP KR US)
A61K 31/513 (2013.01 - EP US); **A61K 31/519** (2013.01 - EP US); **A61K 31/7072** (2013.01 - EP US); **A61K 45/06** (2013.01 - EP KR US); **A61P 35/00** (2017.12 - EP); **A61P 35/02** (2017.12 - EP); **A61P 43/00** (2017.12 - EP); **C07D 239/54** (2013.01 - EP KR US); **C07D 405/12** (2013.01 - EP KR US)

Citation (search report)
• [E] EP 2295414 A1 20110316 - TAIHO PHARMACEUTICAL CO LTD [JP] & DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 10 December 2009 (2009-12-10), FUKUOKA, MASAYOSHI ET AL: "Preparation of novel uracil compounds having inhibitory activity on human deoxyuridine triphosphatase or salts thereof", XP002756470, retrieved from STN Database accession no. 2009:1533808
• [E] WO 2011065545 A1 20110603 - TAIHO PHARMACEUTICAL CO LTD [JP], et al
• [A] WO 2005065689 A1 20050721 - MEDIVIR AB [SE], et al
• See references of WO 2011065541A1

Cited by
RU2686722C1; US11168059B2; US11174271B2; WO2014107622A1; US10858344B2; US10570100B2; US11198677B2; US10259792B2; US10544105B2; US11124485B2; US10577321B2; US11479531B2; US9809571B2; US10227326B2; US10829457B2; US10889563B2; US11247984B2; US11518746B2; US9790214B2; US10457673B2; US10562860B2; US10570098B2; US11014924B2; US11104649B2; US11584723B2

Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DOCDB simple family (publication)
US 2012225838 A1 20120906; US 8883759 B2 20141111; AU 2010323454 A1 20120621; AU 2010323454 A2 20120614; AU 2010323454 B2 20140508; BR 112012013049 A2 20161122; CA 2782280 A1 20110603; CA 2782280 C 20190226; CN 102612369 A 20120725; CN 102612369 B 20140618; CN 103948599 A 20140730; CN 103948599 B 20160309; EP 2508185 A1 20121010; EP 2508185 A4 20160525; EP 2508185 B1 20200304; EP 3673908 A1 20200701; EP 3673908 B1 20220112; ES 2788549 T3 20201021; ES 2906227 T3 20220413; HK 1171185 A1 20130322; HK 1195733 A1 20141121; JP 5336606 B2 20131106; JP WO2011065541 A1 20130418; KR 101701549 B1 20170201; KR 20120116925 A 20121023; MX 2012006183 A 20120619; MY 161094 A 20170414; RU 2012127309 A 20140110; RU 2548913 C2 20150420; TW 201124387 A 20110716; TW I466870 B 20150101; WO 2011065541 A1 20110603

DOCDB simple family (application)
US 201013509102 A 20101129; AU 2010323454 A 20101129; BR 112012013049 A 20101129; CA 2782280 A 20101129; CN 201080051775 A 20101129; CN 201410177136 A 20101129; EP 10833385 A 20101129; EP 20152282 A 20101129; ES 10833385 T 20101129; ES 20152282 T 20101129; HK 12111795 A 20121120; HK 14109161 A 20140911; JP 2010071280 W 20101129; JP 2011543351 A 20101129; KR 20127013820 A 20101129; MX 2012006183 A 20101129; MY PI2012002221 A 20101129; RU 2012127309 A 20101129; TW 99141286 A 20101129